Saturday 17 October 2026
Export IOVA’s income statement to Excel — free account
Iovance Biotherapeutics, Inc.
IOVA Healthcare Biotechnology
Iovance Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $263.5 million, up 60.6% from fiscal 2024. In the quarter to June 2026, revenue grew 65.7%, EPS grew 66.7% and free cash flow grew 11.5%, each against the same quarter a year earlier.
13.58
1.14
−7.74%
Follow IOVA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
3.15 | 3.70 | 5.14 | 5.76 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(10.04) | (18.56) | (20.38) | (30.78) | |
P/B ratio |
1.12 | 1.40 | 2.04 | 2.54 | |
Price to Tangible BV |
1.89 | 2.33 | 3.25 | 3.97 | |
EV/Sales |
1.96 | 2.58 | 4.05 | 4.85 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.52) | (2.25) | (4.27) | (5.97) | |
EV/FCF |
(1.39) | (2.02) | (3.79) | (5.32) | |
Quick Ratio |
2.92 | 2.74 | 3.05 | 3.74 | |
Current Ratio |
3.41 | 3.20 | 3.60 | 4.35 | |
Net Debt/EBITDA |
3.53 | 4.78 | 4.44 | 6.76 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.26 | 0.29 | 0.30 | 0.36 | |
Operating CF/Net income |
0.86 | 0.73 | 0.91 | 1.29 | |
Capex/Depreciation |
(1.11) | (0.82) | (0.63) | (0.69) | |
Research and Development Expense of Revenue |
111.44% | 82.06% | 87.48% | 59.26% | |
Selling, General and Administrative Expense of Revenue |
51.23% | 41.95% | 54.53% | 39.54% | |
Intangible Assets out of Total Assets |
0.32 | 0.31 | 0.29 | 0.29 | |
Share Based Compensation of Revenue |
17.64% | 13.62% | 15.78% | 11.81% | |
Graham Net Nets |
0.29 | 0.23 | 0.18 | 0.15 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(55.30%) | (41.03%) | (27.07%) | (17.55%) | |
Free Cash Flow Yield |
(44.54%) | (34.47%) | (20.76%) | (15.83%) | |
Revenue per Share |
0.19 | 0.24 | 0.17 | 0.22 | |
Operating CF per Share |
(0.22) | (0.15) | (0.17) | (0.14) | |
Capex per Share |
(0.03) | (0.03) | (0.02) | (0.01) | |
Free Cash Flow per Share |
(0.25) | (0.17) | (0.19) | (0.15) | |
Cash per Share |
0.83 | 0.83 | 0.75 | 0.66 | |
Shareholders Equity per Share |
1.93 | 1.95 | 1.72 | 1.64 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.93 | 1.95 | 1.72 | 1.64 | |
Free Cash Flow |
(89.55) | (61.88) | (78.68) | (66.28) | |
Working Capital |
303.31 | 304.33 | 337.08 | 357.41 | |
Capital Expenditures |
(10.84) | (9.32) | (6.61) | (5.44) | |
Net Current Asset Value |
226.43 | 228.10 | 262.59 | 284.77 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.16 | 0.11 | 0.09 | 0.05 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
61.26 | 75.89 | 76.35 | 81.03 | |
Average Payables |
31.46 | 24.83 | 32.97 | 29.11 | |
Average Inventory |
45.14 | 51.60 | 61.96 | 52.71 | |
Average Assets |
948.03 | 911.80 | 946.20 | 911.48 | |
Average Common Equity |
737.87 | 704.49 | 744.81 | 717.26 |
Columns are period end dates